Stay updated on Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe NIH banner about terminology changes and transition updates has been removed from above the study record. The page itself still displays a 403 Forbidden error.SummaryDifference1%

- Check17 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” It appears above the unavailable study record and does not provide study-specific information.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2; the study record page continues to display a 403 error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home button. This replaces the previously visible study record content and related information on the page.SummaryDifference20%

Stay in the know with updates to Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.